First patient dosed with non-opioid therapy for OA pain in Centrexion Therapeutics' Phase 3 clinical trial: 4 insights

Written by Shayna Korol | February 23, 2018 | Print  |

The first patient in Centrexion Therapeutics Corp.'s Phase 3 VICTORY-1 clinical trial has been dosed with CNTX-4975, a synthetic trans-capsaicin injection for the treatment of chronic moderate to severe pain due to knee osteoarthritis.

Here are four things to know:


1. Centrexion Therapeutics is a company focused on developing non-opioid, non-steroidal therapeutics for chronic pain treatment.


2. CNTX-4975 is a highly differentiated, novel non-opioid therapy designed to be injected directly into the painful joint to provide fast-acting and long-lasting pain relief without the risk of abuse and addiction. The FDA granted it Fast Track designation for the treatment of moderate to severe pain associated with knee OA.


3. The Phase 3 trial is a randomized, double-blind, placebo-controlled, 52-week study to evaluate the safety and efficacy of a single injection of CNTX-4975 in patients with chronic OA knee pain. Researchers will enroll approximately 325 patients between 40 and 95 years of age. The study will measure the change in pain with walking at week 12, among other endpoints.


4. CNTX-4975 works by targeting the capsaicin receptor to inactivate the local pain fibers transmitting signals to the brain. With a short half-life, CNTX-4975 is cleared from the body within 24 hours. This approach is designed to provide lasting relief until the ends of the local pain fibers regenerate while maintaining normal sensation without the risks associated with opioid treatment.


More information about VICTORY-1 can be found here under trial identifier NCT03429049.


More articles on biologics:

Bone Therapeutics completes recruitment for spinal fusion study: 4 things to know

Positive clinical trial results for human dermal fibroblast injection CybroCell: 7 key insights

Stempeutics Research inks deal with Alkem Laboratories for osteoarthritis drug: 3 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers